A study to evaluate the effect of selected Siddha drugs in the management of Diabetes at National Institute of Siddha

An Open Labelled Single Centric Non-Randomized Clinical Trial to Evaluate the Therapeutic Efficacy of Selected Siddha Formulations for Management of Type II Diabetes Mellitus (Madhumegam) in Patients Reporting at National Institute of Siddha - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/086821

Enrollment

330

Registered

2025-05-13

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications

Interventions

Intervention1: 1 AvaraiKudineer 2 ThriphalaChooranam 3 KeezhanelliChooranam 4 Madhumegam : 1 AvaraiKudineer 60ml Twice a day (Before Food ) 2 ThriphalaChooranam Tablet 2 Twice a day (After Food)

Eligibility

Inclusion criteria

Inclusion criteria: Sex: Both Males and Females with age 23-65 years Non-Insulin Dependent Diabetes Mellitus with Glycosylated hemoglobin (HbA1c) less than 12 percentage with or without Medication. Patient willing to give blood and urine samples before and after the treatment. Willing to participate in the Study and signing consent by fulfilling the condition of Proforma.

Exclusion criteria

Exclusion criteria: Glycosylated hemoglobin (HbA1c) greater than 12.1% Uncontrolled Hypertension Insulin Dependent Diabetes Mellitus Any other serious Systemic Diseases Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Reduction in HbA1c from baseline to endpoint.Timepoint: 12 months	—

Secondary

Measure	Time frame
Reduction in FBS, PPBS, Urine Sugar of patients from baseline and endpoint. Reduction in HOMA-IR of patients from baseline and endpoint. Improvement in Serum Insulin. Reduction in Microalbuminuria or Macroalbuminuria of patients from baseline and endpoint. Improvement in Quality of life in patients from baseline and endpoint Timepoint: 12 months	—

Countries

India

Contacts

Public ContactDr R GAYATRI

National Institute of Siddha

spaargavi@gmail.com9789452792

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026